1. Home
  2. KEN vs VRDN Comparison

KEN vs VRDN Comparison

Compare KEN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kenon Holdings Ltd.

KEN

Kenon Holdings Ltd.

HOLD

Current Price

$79.32

Market Cap

3.6B

Sector

Utilities

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$27.81

Market Cap

3.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KEN
VRDN
Founded
2014
2006
Country
Singapore
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KEN
VRDN
Price
$79.32
$27.81
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
$41.42
AVG Volume (30 Days)
14.6K
1.4M
Earning Date
04-01-2026
02-27-2026
Dividend Yield
6.06%
N/A
EPS Growth
177.70
N/A
EPS
8.96
N/A
Revenue
$803,304,000.00
$70,789,000.00
Revenue This Year
N/A
$26,080.80
Revenue Next Year
N/A
$2.07
P/E Ratio
$8.54
N/A
Revenue Growth
8.15
23340.07
52 Week Low
$27.10
$9.90
52 Week High
$79.48
$34.29

Technical Indicators

Market Signals
Indicator
KEN
VRDN
Relative Strength Index (RSI) 67.62 34.99
Support Level $71.30 $28.44
Resistance Level $79.48 $30.50
Average True Range (ATR) 1.69 1.47
MACD 0.27 -0.41
Stochastic Oscillator 87.18 7.29

Price Performance

Historical Comparison
KEN
VRDN

About KEN Kenon Holdings Ltd.

Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Share on Social Networks: